PARP1 and prostate carcinoma: In prostate cancer cells piperidine treatment inhibits PC3 cell migration by upregulating E-cadherin and downregulating N-cadherin and Vimentin, whereas piperine treatment to prostate cancer cells shows other activities like activating the caspase-3-dependent apoptotic pathway, suppressing phosphorylated STAT-3, down-regulation of the expression of Nf-κB, inducing PARP-1 cleavage and inhibition of B16-F10 invasion.